{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Participants received single doses of rituximab 750 mg/m\\^2 IV at Weeks 1 through 5, and 7, 9, 11, 14, 16, 18, 20, and 22; cytarabine 2 g/m\\^2 IV every 24 hours for 2 doses at Weeks 11 and 22; and single doses of MTX 8 g/m\\^2 IV at Weeks 3, 5, 7, 9, 14, 16, 18, and 20.","id":"OG000","title":"Rituximab, Cytarabine, and MTX"}],"populationDescription":"Due to early study termination, all efficacy data were documented by data listings only, no data analysis was performed.","reportingStatus":"POSTED","timeFrame":"Week 24","title":"Percentage of Participants With Initial CR or CRu and Subsequent Disease Relapse","type":"SECONDARY"}